Why is "Busulfan" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-03-12 02:01:09
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
Busulfan is a chemotherapy drug in use since 1959. It is a cell cycle non-specific alkylating antineoplastic agent, in the class of alkyl sulfonates. Its chemical designation is 1,4-butanediol dimethanesulfonate.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Busulfan pharmacokinetics in adults – a real-world evaluation of intra -individual variability and the impact of obesity and deferasirox - Nature
-
Novel Conditioning Strategies Emerge in Gene Therapy, Leaving Busulfan—and Toxicities—Behind - Pharmacy Times
-
Positive results for Casgevy but with one patient death from myeloablative busulfan conditioning | ASH 2025 - Managed Healthcare Executive
-
Population Pharmacokinetics of Busulfan in Pediatric Patients: Optimization of a Four-Times-Daily Dosing Regimen Based on EBMT Recommendations - Wiley Online Library
-
Irradiation- and busulfan-free stem cell transplantation in Fanconi anemia using an anti-CD117 antibody: a phase 1b trial - Nature
-
Busulfan-Enhanced VRd Regimen Improves Efficacy in NDMM - CancerNetwork
-
Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1 - The New England Journal of Medicine
-
Novel, Less Toxic, Stem Cell Transplant Prep Yields Successful Outcomes - Genetic Engineering and Biotechnology News
-
Stem cell transplant without toxic preparation successfully treats genetic disease - Medical Xpress
-
Reduced relapse rate and improved GVHD/relapse free survival (GRFS) with pharmacokinetics-guided busulfan conditioning regimen for allogeneic stem cell transplantation in adult patients with myeloid hematologic malignancies - Nature
-
Thiotepa-busulfan-fludarabine compared to clofarabine-based conditioning for haploidentical transplant with posttransplant cyclophosphamide in patients with myeloid malignancies: a retrospective study from the SFGM-TC | Bone Marrow Transplantation - Nature
-
Mechanisms underlying seizures and hypothermia during busulphan administration | Bone Marrow Transplantation - Nature
-
Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation - Nature
-
Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial | Blood Cancer Journal - Nature
-
A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT) - Nature
-
Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan | Bone Marrow Transplantation - Nature
-
Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial | Bone Marrow Transplantation - Nature
-
Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea - Nature
-
Pharmacometabolomics for predicting variable busulfan exposure in paediatric haematopoietic stem cell transplantation patients - Nature
-
Busulfan and cyclophosphamide for autologous stem cell transplantation in patients with multiple myeloma after proteasome inhibitor and/or immunomodulatory drug treatment - Nature
-
Patient With Sickle Cell Disease Dies From Complications Related to Busulfan-Conditioning Following Treatment With Beam’s Base-Editing HSC Therapy BEAM-101 - CGTLive®
-
In vivo enrichment of busulfan-resistant germ cells for efficient production of transgenic avian models - Nature
-
Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01 - Nature
-
Busulfan conditioning and prognostic impact of jaundice in late-onset sinusoidal obstruction syndrome following allogeneic hematopoietic cell transplantation - Nature
-
UPLC-Tandem Mass Spectrometry for Quantification of Busulfan in Human Plasma: Application to Therapeutic Drug Monitoring - Nature
-
Busulfan and cyclosphamide induce liver inflammation through NLRP3 activation in mice after hematopoietic stem cell transplantation - Nature
-
Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to registry data comparison | Bone Marrow Transplantation - Nature
-
High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas | Bone Marrow Transplantation - Nature
-
Busulfan associated pulmonary toxicity: A benign mimic of squamous cell carcinoma diagnosed in a bronchoalveolar lavage specimen - Wiley Online Library
-
Is pharmacokinetic guidance a must in busulfan regimens? - The Lancet
-
Sitagliptin ameliorates busulfan-induced pulmonary and testicular injury in rats through antioxidant, anti-inflammatory, antifibrotic, and antiapoptotic effects - Nature
-
Quality of Life With Busulfan and Fludarabine Compared With Busulfan and Cyclophosphamide - Hematology Advisor
-
Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia | Bone Marrow Transplantation - Nature
-
Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: Results of a multicenter prospective phase 2 trial - Wiley
-
Allo-SCT, Myeloablative Conditioning With Busulfan/Fludarabine Improves Survival in Myelofibrosis - Pharmacy Times
-
Intravenous Busulfan Plus Melphalan vs Melphalan Alone as a Conditioning Regimen in Multiple Myeloma: Is There a Difference? - Cancer Therapy Advisor
-
Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma - Nature
-
Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leuke - Nature
-
Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status - Nature
-
Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the Transplant Complications Working Party of the EBMT - Nature
-
Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS - Nature
-
Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Par - Nature
-
Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children - Nature
-
Fractionated Busulfan Improves NRM and Survival in AML and MDS - Hematology Advisor
-
Experimental and computational studies on possibility of using glucose diazacrown cryptand as a carrier for anticancer drugs busulfan and lomustine - Nature
-
Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of - Nature
-
Thiotepa, busulfan and fludarabine conditioning regimen for adult patients with lymphoid malignancies undergoing allogeneic stem cell transplantation: a study on behalf of GETH-TC | Bone Marrow Transplantation - Nature
-
Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation - Nature
-
Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leuke - Nature
-
Implementing therapeutic drug monitoring for busulfan: expert recommendations - Hospital Pharmacy Europe
-
Myeloablative fractionated busulfan feasible as pre-HSCT regimen for older patients - Healio
-
Myelofibrosis Patients Treated With Fludarabine, Busulfan, TBI Saw Reduction in Graft Failures - Cancer Nursing Today
-
Ferritinophagy-mediated ferroptosis of spermatogonia is involved in busulfan-induced oligospermia in the mice - ScienceDirect.com
-
Atypical cytological changes mimicking SIL of the uterine cervix in allogenic hematopoietic stem cell transplantation recipients treated with busulfan - Wiley
-
Companies launch generic busulfan in US - MDEdge
-
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant - OncLive
-
Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Workin - Nature
-
Busulfan target exposure attainment in children undergoing allogeneic hematopoietic cell transplantation: a single day versus a multiday therapeutic drug monitoring regimen - Nature
-
Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acut - Nature
-
Protective effect of L-carnitine and L-arginine against busulfan-induced oligospermia in adult rat - Wiley Online Library
-
Reduced-toxicity myeloablative conditioning regimen using fludarabine and full doses of intravenous busulfan in pediatric patients not eligible for standard myeloablative conditioning regimens: Results of a multicenter prospective phase 2 trial - Nature
-
Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children - Nature
-
Busulfan plus cyclophosphamide vs. total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia: a large-scale propensity score matching-based study - Nature
-
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS - CancerNetwork
-
Busulfan–melphalan in high-risk neuroblastoma: the 30-year experience of a single institution - Nature
-
Treosulfan May Offer a New Standard for Prehematopoietic Stem Cell Transplantation Conditioning - Hematology Advisor
-
Two-Plus-Three-Agent Conditioning Regimen for Allogeneic SCT in MDS, AML Brings Promising PFS Result - Docwire News
-
Treosulfan-based or busulfan-based conditioning for allogeneic transplantation: the role of dose intensity - The Lancet
-
Mylan/Aspen launch generic busulfan injection - Generics and Biosimilars Initiative
-
Red-Fleshed Apple Anthocyanin Extracts Attenuate Male Reproductive System Dysfunction Caused by Busulfan in Mice - Frontiers
-
An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease - Nature
-
Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin - Nature
-
Intravenous Busulfan-Melphalan Combo May Be As Effective As Melphalan Prior To Stem Cell Transplant In Multiple Myeloma - The Myeloma Beacon
-
Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity - Nature
-
Personalized chemotherapy dosing treatment improves responses, minimizes side effects - UT MD Anderson
-
Busulfan role in Bluebird’s woes could impact gene therapy sector - BioProcess International
-
Sickle cell patient dies in Beam study of base editing therapy - BioPharma Dive
-
Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation – a retrospective analysis - Nature
-
A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation - Nature
-
Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience - Nature
-
Intensified conditioning regimens with total marrow irradiation/etoposide/cyclophosphamide and busulfan/etoposide/cyclophosphamide overcome the impact of pre-transplant minimal residual disease on outcomes in high-risk acute lymphoblastic leukemia pat - Wiley Online Library
-
Treosulfan-based conditioning vs. low-dose busulfan-based conditioning for allogeneic hematopoietic stem cell transplantation: a cost-utility analysis in Poland | Kawalec | Acta Haematologica Polonica - Via Medica Journals
-
Treosulfan-based conditioning vs. low-dose busulfan-based conditioning for allogeneic hematopoietic stem cell transplantation: a cost-utility analysis in Poland | Kawalec | Acta Haematologica Polonica - Via Medica Journals
-
Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT | Bone Marrow Transplantation - Nature
-
FDA Approves Treosulfan as Part of AML/MDS Conditioning Regimen - MedPage Today
-
Transplantation chemotherapy eliminates regenerative capacity of brain’s innate immune cells - Institut Pasteur
-
The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation | Bone Marrow Transplantation - Nature
-
G-CSF-Based Conditioning Regimen Recommended in MDS, Secondary AML Prior to HSCT - Hematology Advisor
-
Alternative Antiepileptic Medications May Be Safe in Adults Receiving Allogeneic Hematopoietic Cell Transplantation - Hematology Advisor
-
Pharmacokinetic and clinical outcomes when ideal body weight is used to dose busulfan in obese hematopoietic stem cell transplant recipients - Nature
-
Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation - Nature
-
Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation - Nature
-
Conditioning treatment regimens for hematopoietic stem cell transplantation - Fred Hutchinson Cancer Center
-
Influence of GST gene polymorphisms on busulfan pharmacokinetics in children - Nature
-
I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients - Nature
-
Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease - Nature
-
Unexpectedly high AUC levels in a child who received intravenous busulfan before stem cell transplantation - Nature
-
Marrow Transplantation for Acute Nonlymphocytic Leukemia after Treatment with Busulfan and Cyclophosphamide - The New England Journal of Medicine
-
Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation - Nature
-
Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft - Nature
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.